|  | Individuals (n) | (%) | ||
---|---|---|---|---|---|
Baseline sample characteristics (n = 9577) | |||||
 Female |  | 1917 | 20% | ||
Period of diagnosis: | |||||
 < 1996 |  | 1297 | 13.5% | ||
 1997–1999 |  | 2186 | 22.8% | ||
 2000–2003 |  | 1657 | 17.3% | ||
 2004–2007 |  | 1789 | 18.7% | ||
 2008–2014 |  | 2648 | 27.6% | ||
HIV risk group: | |||||
 PWID |  | 2363 | 24.7% | ||
 MSM |  | 3116 | 32.5% | ||
 MWID |  | 753 | 7.9% | ||
 HETa |  | 3345 | 34.9% | ||
Age (median) |  | 45.5 | – | ||
 | Cost Component | ||||
Hospitalization | Physician Billings | Non-ART Prescriptions | ART Prescriptions | Total Costs | |
Zero-cost observations (%) | 94.6% | 13.4% | 34.8% | 27.6% | 5.0% |
Positive-cost observations | |||||
 Mean | $14,273 | $530 | $711 | $4741 | $5712 |
 SD | ($19,635) | ($946) | ($1376) | ($1260) | ($7005) |
 Skewness | 4.2 | 7.7 | 9.4 | 1.9 | 10.7 |
 Kurtosis | 28.8 | 99.1 | 202.6 | 7 | 213.5 |
 50th percentile | $7629 | $287 | $239 | $4689 | $5262 |
 99th percentile | $96,497 | $4638 | $5519 | $9884 | $31,362 |